-
Obesity is a growing problem in the united states. the pun would be funny were it not for the adverse influence that the obesity epidemic has had on health care outcomes.
-
In this issue: Escitalopram for menopausal hot flashes, rifaximin for IBS without constipation, herpes zoster vaccination, antiepileptics drugs and fracture risk, and FDA Actions.
-
Ova-301 was a large (n = 672), open-label phase III trial comparing pegylated liposomal doxorubicin (PLD) to combination PLD and trabectedin (PT) in women with recurrent ovarian cancer. The trial's overall population was previously reported and demonstrated a significant impact on PFS, without a significant improvement in OS.
-
Despite the important progress that has been made in obstetrics, in general, over the last 20 years, shoulder dystocia remains an enigma. Given the rising rate of maternal obesity and gestational diabetes, it is unlikely that the rate of this dangerous complication will be lowered in the near future.
-
-
-
As a growing number of quality initiatives have shown, quick change can be effective change, and that certainly appears to be the case with VHA Inc.'s
-
The proper process for handoffs is outlined in The Joint Commission standard PC.02.0201.EP2, notes Carol Mooney, RN, MSN, senior associate director at the Standards and Interpretation Group, who adds that they formerly were covered under a National Patient Safety Goal.
-
-
The advent of true value-based purchasing focused not just on reporting data but on actual outcomes took a major step closer to reality with the issuance of a proposed rule by the Centers for Medicare & Medicaid Services (CMS), the final version of which would take effect starting in fiscal year 2013.
